Description
An irreversible pan-ErbB receptor tyrosine kinase inhibitor (IC50s = 6, 45.7, and 73.7 nM for ErbB1, ErbB2, and ErbB4, respectively); demonstrates antitumor activity in various tumor xenograft models expressing either wild-type ErbB or mutant ErbB family members that show resistance to first generation ErbB kinase inhibitors
Formal name: N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-(2E)-butenamide
Synonyms: Dacomitinib|PF299
Molecular weight: 469.9
CAS: 1110813-31-4
Purity: ≥98%
Formulation: A crystalline solid